The BIOSECURE Act, proposed in the US House and Senate this year, is poised to significantly impact the Contract Development and Manufacturing Organization (CDMO) industry. The legislation specifically targets Wuxi Apptec and Wuxi Biologics, raising concerns about potential repercussions. Market fears suggest similar sanctions might be imposed on other Chinese CDMOs, including Wuxi Biologics.

According to a survey by the Biotechnology Innovation Organization (BIO), 79% of the 124 biotech companies surveyed have had at least one CDMO contract with Chinese firms. If future contracts with Chinese CDMOs are prohibited, ongoing production projects could face significant disruptions, prompting companies to urgently seek alternatives.

This scenario, however, presents new opportunities. As US biotech firms have relied heavily on Chinese CDMOs, there is now a keen interest in who will secure the displaced contracts. The CDMO industry landscape at BIO USA this year could be reshaped by the implications of the BIOSECURE Act.

Several CDMOs have declared their intention to leverage this legislation to their advantage, using the BIO USA event for promotion. Samsung Biologics, for instance, has emphasized its Contract Development Organization (CDO) brand to replace the market position of Wuxi Biologics and secure long-term revenue over the next 20 years.

However, relying solely on CDO projects is unlikely to significantly boost revenue. Unlike Contract Manufacturing Organization (CMO) projects that focus on production, CDO projects emphasize development, offering higher added value but smaller contract scales. Optimizing production techniques through CDO projects increases the likelihood that clients will continue using the same CDMO throughout the preclinical, clinical, and commercialization stages. This strategy could lead to stable CMO revenue during the preclinical and clinical development phases and substantial revenue post-launch from large-scale production.

This approach mirrors the strategy previously implemented by Wuxi Biologics, which started with a focus on CDO and gradually strengthened its CMO capabilities. Samsung Biologics appears to be adopting a similar strategy, prompted by the momentum created by the BIOSECURE Act.

Prestige Biologics stood out at BIO USA with their eye-catching jade green suits and unique strategy of offering a "Full Value Chain CDMO." The Prestige Biopharma Group handles the entire cycle of new drug research, development, and production, integrating expertise into their CDMO projects effectively.

This strategy offers intriguing insights when compared to Samsung Biologics. Samsung Biologics could also claim to be a "Full Value Chain CDMO" since its subsidiary, Samsung Bioepis, develops biosimilars. Moreover, Samsung Bioepis has already received approvals and is selling products, which gives it more experience compared to the Prestige Biopharma Group.

However, it appears that Samsung Biologics is not emphasizing this aspect. Some believe it is due to concerns about client perceptions. Clients may worry about the potential for technology leakage when they entrust product manufacturing to a CDMO that is affiliated with a drug development company. Although confidentiality agreements (CDAs) are always in place to mitigate legal risks, these concerns are not easily dispelled.

In contrast, the Prestige Biopharma Group seems to be tackling this issue head-on. By emphasizing their full value chain from the start, they may believe they can gradually alleviate client concerns. 

This approach highlights a key difference between the two companies: while Samsung Biologics opts for caution, Prestige Biopharma Group is more aggressive in leveraging its comprehensive capabilities, believing that initial transparency and subsequent reassurance will ultimately attract and retain clients.

However, the primary reason Prestige Biologics attracted significant interest is its advantageous position to benefit indirectly from the BIOSECURE Act. Their production processes are nearly identical to those of Wuxi Biologics.

Of Wuxi Biologics' total production capacity of 300,000 liters, 160,000 liters utilize "single-use" technology. This method involves connecting up to five 2,000-liter bioreactors in parallel, producing up to 10,000 liters at once. The process involves placing large plastic bags inside the bioreactors to produce pharmaceuticals, which are discarded after production. The advantages of this method include:

① Contamination Control: If contamination occurs, only the affected bioreactor is isolated, allowing the remaining production to continue.

② Flexibility: The use of disposable bags reduces the time required to switch between different products.

③ Efficiency: Being a relatively modern method, it offers higher yields compared to traditional stainless-steel bioreactors.

Prestige Biologics employs a very similar production technique. They connect up to four 2,000-liter bioreactors in parallel, producing up to 8,000 liters at once, and also use single-use technology with disposable bags.

This similarity makes Prestige Biologics a natural alternative for companies that previously used Wuxi Biologics' CMO services. If they need to change production sites due to the BIOSECURE Act, choosing a site with similar processes minimizes risks. This positioning is why Prestige Biologics is poised to gain from the disruptions caused by the new legislation.

This production method gives Prestige Biologics an additional strategic advantage, particularly when compared to Samsung Biologics. Samsung Biologics uses 15,000-liter stainless steel bioreactors, which allows them to handle large-scale orders and produce large quantities in one go. However, this makes it challenging for them to produce smaller quantities of various products, and this isn't part of their strategic focus.

In contrast, Prestige Biologics' use of single-use technology enables them to produce small quantities of a wide variety of products. This means they don't have to compete directly with industry giants like Samsung Biologics for antibody drug CMO projects. Instead, they can cater to multiple smaller biotech companies, securing numerous CMO contracts. As these clients progress through preclinical and clinical phases, Prestige Biologics can expand their facilities to prepare for larger-scale contracts.

The BIOSECURE Act has introduced both challenges and opportunities for the CDMO industry. As companies navigate this new landscape, those like Samsung Biologics and Prestige Biologics are strategically positioning themselves to capture the displaced market share and secure long-term growth.